<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03980769</url>
  </required_header>
  <id_info>
    <org_study_id>RG1005072</org_study_id>
    <secondary_id>NCI-2019-03243</secondary_id>
    <secondary_id>9621</secondary_id>
    <nct_id>NCT03980769</nct_id>
  </id_info>
  <brief_title>Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Thiotepa in Treating Patients With Non-malignant Disorders</brief_title>
  <official_title>Allogeneic Hematopoietic Cell Transplantation for Patients With Non-Malignant Disorders Using Treosulfan, Fludarabine, and Thiotepa</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Fred Hutchinson Cancer Research Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Fred Hutchinson Cancer Research Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This phase II clinical trial studies how well treosulfan, thiotepa, fludarabine, and rabbit&#xD;
      anti-thymocyte globulin (rATG) before donor stem cell transplantation works in treating&#xD;
      patients with nonmalignant (non-cancerous) diseases. Hematopoietic cell transplantation has&#xD;
      been shown to be curative for many patients with nonmalignant (non-cancerious) diseases such&#xD;
      as primary immunodeficiency disorders, immune dysregulatory disorders, hemophagocytic&#xD;
      lymphohistiocytosis, bone marrow failure syndromes, and hemoglobinopathies. Powerful&#xD;
      chemotherapy drugs are often used to condition the patient before infusion of the new healthy&#xD;
      donor cells. The purpose of the conditioning therapy is to destroy the patient's abnormal&#xD;
      bone marrow which doesn't work properly in order to make way for the new healthy donor cells&#xD;
      which functions normally. Although effective in curing the patient's disease, many&#xD;
      hematopoietic cell transplantation regimens use intensive chemotherapy which can be quite&#xD;
      toxic, have significant side effects, and can potentially be life-threatening. Investigators&#xD;
      are investigating whether a new conditioning regimen that uses less intensive drugs&#xD;
      (treosulfan, thiotepa, and fludarabine phosphate) results in new blood-forming cells&#xD;
      (engraftment) of the new donor cells without increased toxicities in patients with&#xD;
      nonmalignant (non-cancerous) diseases.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OUTLINE:&#xD;
&#xD;
      Patients receive thiotepa intravenously (IV) twice daily (BID) on day -7, treosulfan IV on&#xD;
      days -6 to -4, fludarabine phosphate IV on days -6 to -2, and rabbit anti-thymocyte globulin&#xD;
      IV on days -4 to -2. Patients then undergo allogeneic hematopoietic cell transplant via&#xD;
      infusion on day 0.&#xD;
&#xD;
      After completion of study treatment, patients are followed up at 1 year and then annually&#xD;
      thereafter.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 5, 2021</start_date>
  <completion_date type="Anticipated">July 1, 2027</completion_date>
  <primary_completion_date type="Anticipated">July 1, 2027</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Engraftment failure</measure>
    <time_frame>1 year after transplant</time_frame>
    <description>Will be defined as donor CD3 chimerism &lt; 5% at 1 year after transplant.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>At 1 year post-transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Event-free survival</measure>
    <time_frame>At 1 year post-transplant</time_frame>
    <description>Defined as death due to any cause, donor lymphocyte infusion, CD34 boost, second transplant, graft rejection or graft failure, or the development of myelodysplastic syndrome or leukemia following transplant (whichever event occurs first).</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Transplant-related mortality</measure>
    <time_frame>At day 100 after transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of grade II-IV acute graft-versus-host disease</measure>
    <time_frame>At day 100 after transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of chronic graft-versus-host disease</measure>
    <time_frame>At 1 year after transplant</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Donor chimerism CD3 &amp; CD33</measure>
    <time_frame>At 1 year after transplant</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">40</enrollment>
  <condition>Non-Neoplastic Hematologic and Lymphocytic Disorder</condition>
  <arm_group>
    <arm_group_label>Treatment (chemotherapy, transplant)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive thiotepa IV BID on days -7, treosulfan IV on days -6 to -4, fludarabine phosphate IV on days -6 to -2, and rabbit anti-thymocyte globulin IV on days -4 to -2. Patients then undergo allogeneic hematopoietic cell transplant via infusion on day 0.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Thiotepa</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemotherapy, transplant)</arm_group_label>
    <other_name>1,1',1&quot;-phosphinothioylidynetrisaziridine</other_name>
    <other_name>N,N', N''-Triethylenethiophosphoramid</other_name>
    <other_name>Oncotiotepa</other_name>
    <other_name>STEPA</other_name>
    <other_name>Tepadina</other_name>
    <other_name>TESPA</other_name>
    <other_name>Tespamin</other_name>
    <other_name>Tespamine</other_name>
    <other_name>Thio-Tepa</other_name>
    <other_name>Thiofosfamide</other_name>
    <other_name>Thiofozil</other_name>
    <other_name>Thiophosphamide</other_name>
    <other_name>Thiophosphoramide</other_name>
    <other_name>Thiotef</other_name>
    <other_name>Tifosyl</other_name>
    <other_name>TIO TEF</other_name>
    <other_name>Triethylene thiophosphoramide</other_name>
    <other_name>Triethylenethiophosphoramide</other_name>
    <other_name>TSPA</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treosulfan</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemotherapy, transplant)</arm_group_label>
    <other_name>(S-(R*,R*))-1,2,3,4-butanetetrol</other_name>
    <other_name>1,4-dimethanesulfonate</other_name>
    <other_name>[R-(R*,S*)]-, 299-75-2, 39069</other_name>
    <other_name>Dihydroxybusulfan</other_name>
    <other_name>Ovastat</other_name>
    <other_name>Treosulphan</other_name>
    <other_name>Tresulfon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fludarabine Phosphate</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemotherapy, transplant)</arm_group_label>
    <other_name>2-F-ara-AMP</other_name>
    <other_name>312887</other_name>
    <other_name>328002</other_name>
    <other_name>75607-67-9</other_name>
    <other_name>9H-Purin-6-amine</other_name>
    <other_name>2-fluoro-9-(5-O-phosphono-.beta.-D-arabinofuranosyl)-</other_name>
    <other_name>Beneflur</other_name>
    <other_name>Fludara</other_name>
    <other_name>Fludarabine-5'-Monophosphate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Rabbit Anti-Thymocyte Globulin</intervention_name>
    <description>Given IV</description>
    <arm_group_label>Treatment (chemotherapy, transplant)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Allogeneic Hematopoietic Stem Cell Transplantation</intervention_name>
    <description>Undergo HCT via infusion</description>
    <arm_group_label>Treatment (chemotherapy, transplant)</arm_group_label>
    <other_name>Allogeneic Hematopoietic Cell Transplantation</other_name>
    <other_name>Allogeneic Stem Cell Transplantation</other_name>
    <other_name>HSC</other_name>
    <other_name>HSCT</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patient with nonmalignant disease treatable by allogenic HCT&#xD;
&#xD;
          -  Patient with a nonmalignant disease that is not clearly defined (a patient with a&#xD;
             non-malignant disease HCT for whom a genetic mutation responsible for their&#xD;
             non-malignant disease phenotype has not been identified) are eligible for the study&#xD;
             following discussion with and approval by the protocol principal investigator (PI)&#xD;
             (Dr. Lauri Burroughs)&#xD;
&#xD;
          -  DONOR: Human leukocyte antigen (HLA)-identical related donor OR unrelated donor&#xD;
             matched for HLA-A, B, C, DRB1 and DQB1 or mismatched for a single allele at HLA-A, B,&#xD;
             C, or a single DQB1 antigen or allele mismatch by high resolution deoxyribonucleic&#xD;
             acid (DNA) typing&#xD;
&#xD;
          -  DONOR: Bone marrow is the preferred cell source (when feasible). However, peripheral&#xD;
             blood stem cells (PBSC) is also allowed and the PI may determine if PBSC is preferred&#xD;
             for certain patients&#xD;
&#xD;
               -  The recommended total nucleated cell count (TNC) for bone marrow grafts is &gt;= 4.0&#xD;
                  x 10^8 TNC/kg (actual recipient weight)&#xD;
&#xD;
               -  The recommended CD34 cell count for PBSC grafts is &gt;= 5 x 10^6 CD34/kg (actual&#xD;
                  recipient weight) and the recommended maximum CD34 cell count for PBSC grafts is&#xD;
                  10 x 10^6 CD34/kg (actual recipient weight)&#xD;
&#xD;
          -  DONOR: HLA-matched sibling bone marrow in combination with HLA-matched sibling&#xD;
             umbilical cord blood if the HLA-matched sibling umbilical cord blood was collected and&#xD;
             stored. The HLA-matched sibling bone marrow and cord blood would be matched for HLA-A,&#xD;
             B, C, DRB1 and DQB1&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients with idiopathic aplastic anemia and Fanconi anemia; patients with aplastic&#xD;
             anemia associated with paroxysmal nocturnal hemoglobinuria (PNH) or inherited marrow&#xD;
             failure syndromes (except Fanconi anemia) will be allowed&#xD;
&#xD;
          -  Impaired cardiac function as evidenced by ejection fraction &lt; 35% (or, if unable to&#xD;
             obtain ejection fraction, shortening fraction of &lt; 26%) or cardiac insufficiency&#xD;
             requiring treatment or symptomatic coronary artery disease. Patients with a shortening&#xD;
             fraction of &lt; 26% may be enrolled if approved by a cardiologist&#xD;
&#xD;
          -  Impaired pulmonary function as evidenced by carbon monoxide diffusing capability&#xD;
             (DLCO) corrected &lt; 50% of predicted (or, if unable to perform pulmonary function&#xD;
             tests, then oxygen [O2] saturation &lt; 92% on room air)&#xD;
&#xD;
          -  Impaired renal function as evidenced by:&#xD;
&#xD;
               -  Estimated creatinine clearance &lt; 60 mL/min/1.73m^2 using either the Chronic&#xD;
                  Kidney Disease Epidemiology Collaboration (CKD EPI) equation for adult patients&#xD;
                  (&gt;= 18 years old), or the updated Schwartz formula for pediatric patients (&lt; 18&#xD;
                  years old). If the estimated creatinine clearance is &lt; 60 mL/min/1.73m^2, then&#xD;
                  renal function must be measured by 24-hour creatinine clearance, Iothalamate,&#xD;
                  Iohexol or nuclear GFR and the patient is excluded if their measured creatinine&#xD;
                  clearance is &lt; 50 mL/min/1.73 m^2, OR&#xD;
&#xD;
               -  Serum creatinine &gt; 2 x upper limit of normal, OR&#xD;
&#xD;
               -  Dialysis dependent&#xD;
&#xD;
          -  Evidence of synthetic dysfunction or severe cirrhosis requiring deferral of&#xD;
             conditioning as recommended by a gastroenterology specialist&#xD;
&#xD;
          -  Active infectious disease requiring deferral of conditioning as recommended by an&#xD;
             infectious disease specialist&#xD;
&#xD;
          -  Positive for HIV (human immunodeficiency virus)&#xD;
&#xD;
          -  Females who are pregnant or breast-feeding&#xD;
&#xD;
          -  Known hypersensitivity to treosulfan, fludarabine, and/or thiotepa&#xD;
&#xD;
          -  DONOR: Donors deemed unable to undergo marrow harvesting of PBSC mobilization and&#xD;
             leukapheresis&#xD;
&#xD;
          -  DONOR: HIV-positive donors&#xD;
&#xD;
          -  DONOR: Donors with active infectious hepatitis&#xD;
&#xD;
          -  DONOR: Female donor with positive pregnancy test&#xD;
&#xD;
          -  DONOR: Donors are excluded if the patient has an identified antibody against a&#xD;
             donor-specific HLA locus as specified in standard practice&#xD;
&#xD;
          -  DONOR: HLA-matched sibling cord blood units that have not passed donor screening for&#xD;
             infectious disease markers as recommended by the National Marrow Donor Project (NMDP)&#xD;
             will not be used unless a waiver is signed by the clinical attending allowing use of&#xD;
             cord blood unit. Cord blood units are presumed to be cytomegalovirus (CMV) negative&#xD;
             regardless of serologic testing due to passive transmission of maternal CMV antibodies&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>49 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lauri Burroughs</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fred Hutch/University of Washington Cancer Consortium</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Lauri Burroughs</last_name>
    <phone>206-667-2396</phone>
    <email>lburroug@fredhutch.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Fred Hutch/University of Washington Cancer Consortium</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lauri Burroughs</last_name>
      <phone>206-667-2396</phone>
      <email>lburroug@fredhutch.org</email>
    </contact>
    <investigator>
      <last_name>Lauri Burroughs</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Medical College of Wisconsin</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53226</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Julie-An Talano</last_name>
      <phone>414-456-4170</phone>
    </contact>
    <investigator>
      <last_name>Julie-An Talano</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>June 6, 2019</study_first_submitted>
  <study_first_submitted_qc>June 6, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 10, 2019</study_first_posted>
  <last_update_submitted>October 7, 2021</last_update_submitted>
  <last_update_submitted_qc>October 7, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 15, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hematologic Diseases</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Vidarabine</mesh_term>
    <mesh_term>Fludarabine</mesh_term>
    <mesh_term>Fludarabine phosphate</mesh_term>
    <mesh_term>Thiotepa</mesh_term>
    <mesh_term>Treosulfan</mesh_term>
    <mesh_term>Busulfan</mesh_term>
    <mesh_term>Antilymphocyte Serum</mesh_term>
    <mesh_term>Thymoglobulin</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

